Histological tumor response predicts clinical outcome in patients with colorectal peritoneal metastasis treated with preoperative chemotherapy followed by cytoreduction and HIPEC.

Autor:	de Sousa IVF; Faculty of Medicine of Porto University, Porto, Portugal., Lopes JMD; Faculty of Medicine of Porto University, Porto, Portugal.; Anatomic Pathology Department, São João University Hospital Center, Porto, Portugal., Nogueiro JPM; Faculty of Medicine of Porto University, Porto, Portugal.; General Surgery Department, São João University Hospital Center, Porto, Portugal., Costa TR; General Surgery Department, Local Health Unit of Guarda, Guarda, Portugal., Barbosa LER; Faculty of Medicine of Porto University, Porto, Portugal.; General Surgery Department, São João University Hospital Center, Porto, Portugal., Aral MMM; Faculty of Medicine of Porto University, Porto, Portugal.; General Surgery Department, São João University Hospital Center, Porto, Portugal.
Jazyk:	angličtina
Zdroj:	Pleura and peritoneum [Pleura Peritoneum] 2023 Mar 27; Vol. 8 (1), pp. 37-44. Date of Electronic Publication: 2023 Mar 27 (Print Publication: 2023).
DOI:	10.1515/pp-2022-0117
Abstrakt:	Objectives: Up to one quarter of the patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PM). The aims of this retrospective study were to characterize the histological response of the PM of CRC to preoperative chemotherapy and evaluate the potential prognostic value, in terms of survival. Methods: This retrospective unicentric study evaluated a group of 30 patients treated between 2010 and 2020 at the São João University Hospital Center with preoperative chemotherapy, followed by cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy. The evaluation of the histological response was done using two scores: the tumor regression grading (TRG) and the peritoneal regression grading score (PRGS). Results: Mean post-procedure survival is higher in the PRGS 1-2 group (74.19 months) vs. the PRGS 3-4 group (25.27 months) (p=0.045), as well as in the TRG 1-2 group (74.58 months) vs. TRG 4-5 (25.27 months) (p=0.032). As for progression-free survival (PFS), the PRGS 1-2 group had a mean value of 58.03 months vs. PRGS 3-4 which had 11.67 months (p=0.002). Similar was observed with the TRG 1-2 group, which had a mean PFS of 61.68 months vs. TRG 4-5 with 11.67 months (p=0.003). Conclusions: A better histological response to preoperative chemotherapy, represented as a lower PRGS and TRG value, is associated with longer post-procedure survival and progression-free survival in this group of patients. That is, these two scores have prognostic value. (© 2023 the author(s), published by De Gruyter, Berlin/Boston.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu